CDNA icon

CareDx

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 66.7%
Negative

Neutral
Business Wire
10 days ago
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new innovations and products that will be featured at The American Society for Histocompatibility and Immunogenetics (ASHI) 2025 Annual Meeting, held October 6th to 10th in Orlando.
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
Neutral
Business Wire
1 month ago
CareDx Issues Comment Letter on Draft LCD Policy
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has submitted its comment letter in response to the draft Local Coverage Determination (LCD) related to molecular testing for solid organ transplant rejection. The comment letter has.
CareDx Issues Comment Letter on Draft LCD Policy
Negative
Benzinga
1 month ago
CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential
CareDx, Inc. CDNA faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company's expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.
CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential
Neutral
Business Wire
1 month ago
CareDx to Participate in Wells Fargo Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, Massachusetts, on September 5, 2025, at 8:00 AM ET. A live and archived webcast of the pres.
CareDx to Participate in Wells Fargo Healthcare Conference
Positive
The Motley Fool
2 months ago
CareDx (CDNA) EPS Beats Sales Gain 14%
CareDx (CDNA) EPS Beats Sales Gain 14%
CareDx (CDNA) EPS Beats Sales Gain 14%
Neutral
Seeking Alpha
2 months ago
CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.
CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
Negative
Zacks Investment Research
2 months ago
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
Neutral
Business Wire
2 months ago
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth p.
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
Neutral
Business Wire
2 months ago
CareDx Announces Second Quarter 2025 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass.
CareDx Announces Second Quarter 2025 Financial Results